Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2013 - 2026)

Amphastar Pharmaceuticals' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $170.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 6.48% year-over-year to $170.9 million; the TTM figure through Mar 2026 stood at $170.9 million (down 6.48% YoY), while the FY2025 annual figure was $170.2 million, up 12.25% from the prior year.
• Cash & Equivalents was $170.9 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $170.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $266.8 million in Q3 2023 to a low of $144.3 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $179.5 million across 5 years, with a median of $172.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 69.91% in 2022, then fell 27.99% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $156.1 million in 2022, then fell by 7.56% to $144.3 million in 2023, then gained by 5.07% to $151.6 million in 2024, then rose by 12.25% to $170.2 million in 2025, then gained by 0.45% to $170.9 million in 2026.
• The last three Cash & Equivalents figures came in at $170.9 million (Q1 2026), $170.2 million (Q4 2025), and $216.3 million (Q3 2025), per Business Quant data.